NEW DELHI, India — Facing nearly 2 million new tuberculosis cases every year — more and more of them drug-resistant — India has a bigger stake in finding a better treatment for TB than any other country. Yet until recently, obstacles hindered Indian scientists' efforts to conduct advanced research. The reason? India's university professors are bogged down with teaching, and few have the laboratory facilities needed to do cutting edge work. And the best minds are lured away by the pharmaceutical industry — which has little interest in TB, from which there is little money to be made. But a pioneering effort to discover new drugs using the “open source” model prevalent in the software industry could change that.